Novartis phase 3 inhaled asthma combo study meets primary, key secondary goals

• Low dose QMF149 (indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to inhaled corticosteroid (ICS) monotherapy[1]
• QUARTZ is the first completed study of the phase III PLATINUM clinical development program which evaluates both QMF149 (indacaterol and mometasone furoate) and QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate)
• Novartis is aiming to reimagine inhaled asthma care by developing once daily fixed dose combination treatments, delivered with the dose-confirming Breezhaler^® device, to help asthma patients achieve better control

https://www.novartis.com/news/media-releases/novartis-phase-iii-quartz-study-new-investigational-inhaled-combination-treatment-qmf149-meets-primary-and-key-secondary-endpoints-patients-inadequately